Core Viewpoint - Gain Therapeutics, Inc. is actively participating in key healthcare conferences to showcase its advancements in allosteric small molecule therapies, particularly focusing on its lead drug candidate GT-02287 for Parkinson's disease [1][2]. Conference Participation - Gain Therapeutics will attend the 44th Annual J.P. Morgan Healthcare Conference and other related events, including the Sachs Neuroscience Innovation Forum on January 11, 2026, and the Demy-Colton/Informa Biotech Showcase from January 12-14, 2026 [1][3]. - The company will conduct presentations and one-on-one meetings with management during these events, providing opportunities for investors and stakeholders to engage directly [3][4]. Drug Development - GT-02287 is in clinical development for treating Parkinson's disease, targeting both patients with and without a GBA1 mutation [5][8]. - The drug functions as an allosteric enzyme modulator, aiming to restore the function of the glucocerebrosidase enzyme, which is often impaired due to genetic mutations or age-related stress [5]. - In preclinical models, GT-02287 has shown promising results, including restoration of enzymatic function and reduction of neurodegeneration biomarkers [5][6]. Clinical Trials - GT-02287 is currently undergoing a Phase 1b clinical trial across seven sites in Australia, focusing on safety and tolerability over a three-month period [6]. - An extension of the Phase 1b study allows participants to continue treatment for up to 12 months, indicating a commitment to long-term evaluation of the drug's effects [6]. Funding and Support - The development of GT-02287 has received funding from notable organizations, including The Michael J. Fox Foundation and the Eurostars-2 program, highlighting the drug's potential and the support it has garnered [7]. Company Overview - Gain Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of next-generation allosteric therapies, with a focus on neurodegenerative diseases and other challenging disorders [8][10]. - The company employs its proprietary Magellan™ platform to accelerate drug discovery and develop novel treatments for various conditions, including lysosomal storage disorders and solid tumors [10].

Core Insights - GH Research PLC shares increased by 18.1% to $15.64 in pre-market trading following the announcement of an update on its FDA IND status and Phase 3 program for GH001 in treatment-resistant depression [1] Gainers - MKDWELL Tech Inc surged 61.2% to $0.27 after agreeing to repurchase 34,580,000 ordinary shares at $0.203/share, totaling $7 million [4] - Regencell Bioscience Holdings Ltd gained 52% to $31.21 after a previous decline of 2% [4] - Datavault AI Inc rose 26.7% to $1.28 after a 55% increase on the previous trading day [4] - Sidus Space Inc increased by 21.9% to $5.28 following a 38% rise on Friday [4] - Kazia Therapeutics Ltd rose 21.7% to $6.08 after a 27% decline on Friday [4] - Context Therapeutics Inc gained 18.7% to $1.84 after a 5% increase on Friday [4] - Hyperscale Data Inc rose 18.6% to $0.32 after a 49% jump on Friday [4] - PBF Energy Inc increased by 16.7% to $33.30 after providing updates on Martinez refinery operations and 2026 annual guidance [4] - Bioatla Inc rose 16.1% to $0.62 after a dip of more than 5% on Friday [4] Losers - Salarius Pharmaceuticals Inc fell 21.8% to $0.51 in pre-market trading [4] - Gain Therapeutics Inc decreased by 21.4% to $2.50 [4] - SBC Medical Group Holdings Inc declined 18.9% to $3.51 [4] - Polyrizon Ltd dropped 11.7% to $11.24 after a 50% gain on Friday [4] - ChowChow Cloud International HLDG Ltd dipped 10.3% to $0.71 after a 30% increase on Friday [4] - Lavoro Ltd shares fell 9.1% to $1.00 after a 144% jump on Friday [4] - Vicarious Surgical Inc decreased by 7.9% to $2.32 after a 16% gain on Friday [4] - Theravance Biopharma Inc dipped 6% to $17.07 after a 3% decline on Friday [4] - Comcast Corp tumbled 4.6% to $28.18 [4] - Equinor ASA fell 3.6% to $23.66 after a 4% increase on Friday [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - WhiteFiber, Inc. (WYFI) is up 21% at $17.35 [3] - Rising Dragon Acquisition Corp. (RDAC) is up 21% at $12.63 [3] - Julong Holding Limited (JLHL) is up 13% at $3.45 [3] - Linkhome Holdings Inc. (LHAI) is up 11% at $12.50 [3] - A SPAC III Acquisition Corp. (ASPC) is up 9% at $13.09 [3] - Intuitive Machines, Inc. (LUNR) is up 7% at $11.61 [3] - Ascent Solar Technologies, Inc. (ASTI) is up 7% at $3.31 [3] - Bitmine Immersion Technologies, Inc. (BMNR) is up 6% at $30.39 [3] - Velo3D, Inc. (VELO) is up 5% at $12.10 [3] - Gain Therapeutics, Inc. (GANX) is up 4% at $2.36 [3] Premarket Losers - cbdMD, Inc. (YCBD) is down 17% at $1.60 [4] - Mega Fortune Company Limited (MGRT) is down 16% at $7.33 [4] - Cassava Sciences, Inc. (SAVA) is down 14% at $2.43 [4] - NIKE, Inc. (NKE) is down 10% at $59.01 [4] - InMed Pharmaceuticals Inc. (INM) is down 6% at $1.21 [4] - Datacentrex, Inc. (DTCX) is down 5% at $3.23 [4] - Abundia Global Impact Group Inc (AGIG) is down 5% at $1.50 [4] - PSQ Holdings, Inc. (PSQH) is down 5% at $1.00 [4] - Paranovus Entertainment Technology Ltd. (PAVS) is down 4% at $2.34 [4] - Worksport Ltd. (WKSP) is down 4% at $2.09 [4]

Core Viewpoint - Gain Therapeutics, Inc. is advancing its lead drug candidate GT-02287 for the treatment of Parkinson's disease, with a focus on its disease-modifying potential and biomarker data from a Phase 1b clinical study [1][2]. Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of next-generation allosteric therapies [10]. - The company is currently evaluating GT-02287 in a Phase 1b clinical trial for Parkinson's disease, targeting patients with or without a GBA1 mutation [10]. Drug Candidate Details - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric enzyme modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) [5]. - Preclinical studies have shown that GT-02287 can restore GCase enzymatic function and reduce various pathologies associated with Parkinson's disease, including neuroinflammation and neuronal death [5][6]. - The drug has demonstrated a disease-modifying effect in preclinical models, suggesting potential to slow or stop the progression of Parkinson's disease [6]. Clinical Study Insights - The Phase 1 study of GT-02287 in healthy volunteers indicated favorable safety and tolerability, with target engagement reflected in increased GCase activity [7]. - The ongoing Phase 1b clinical trial has enrolled participants across seven sites in Australia, focusing on the safety and tolerability of GT-02287 after three months of dosing [8]. - An extension of the Phase 1b study allows participants to continue treatment for up to 12 months [8]. Funding and Support - Gain Therapeutics has received funding support for its lead program from The Michael J. Fox Foundation for Parkinson's Research and The Silverstein Foundation for Parkinson's with GBA, among others [9].

Core Insights - Gain Therapeutics has successfully enrolled 16 participants in its Phase 1b clinical trial for GT-02287, surpassing the initial goal of 15 participants by Q3 2025 [1][2] - The analysis of 90-day biomarker activity from cerebrospinal fluid (CSF) is now expected to be available in Q4 2025, earlier than the previously planned Q1 2026 [1][2] - The independent data monitoring committee has recommended continuing the study without changes in dose level, with no serious treatment-emergent adverse events reported [1][2] Company Overview - Gain Therapeutics is a clinical-stage biotechnology company focused on developing allosteric small molecule therapies, with GT-02287 as its lead candidate for treating Parkinson's disease [4][9] - The drug is designed to restore the function of the lysosomal enzyme glucocerebrosidase (GCase), which is impaired due to mutations in the GBA1 gene, a common genetic abnormality associated with Parkinson's disease [4][5] Clinical Trial Details - The Phase 1b trial aims to evaluate the safety and tolerability of GT-02287 over a 90-day dosing period in participants with Parkinson's disease, with enrollment ongoing across seven sites in Australia [7][9] - The company plans to extend the screening window for participants until July 31, 2025, and is seeking to extend the dosing period beyond the current 90-day limit [2][3] Preclinical and Clinical Evidence - Preclinical studies have shown that GT-02287 can restore GCase enzymatic function and reduce various pathologies associated with Parkinson's disease, suggesting a potential disease-modifying effect [5][6] - Results from a Phase 1 study in healthy volunteers indicated favorable safety and tolerability, with a greater than 50% increase in GCase activity observed [6][9] Funding and Support - Gain Therapeutics has received funding support from organizations such as The Michael J. Fox Foundation for Parkinson's Research and the Eurostars-2 joint program, which is co-funded by the European Union [8][9]